Milner Therapeutics Institute supports new £20 million MRC Hub to accelerate next-generation drug discovery
The Milner Therapeutics Institute (MTI) is proud to be part of a new £20 million Medical Research Council (MRC) investment that will establish a UK Pre-clinical Translational Models Hub.
Milner Institute convenes science, industry, investors and charity funders for Pitch Day and Symposium
Researchers, entrepreneurs, investors and global pharmaceutical leaders gathered in Cambridge this week as the Milner Therapeutics Institute hosted its annual Pitch Day and 11
Milner Institute joins o2h Discovery Platinum Partner Programme to expand support for emerging biotech companies
Milner Institute joins the o2h Discovery Platinum Partner Programme, enabling eligible companies within its bio-incubator and wider affiliate network to access specialist drug discovery support through the o2h Kickstarter Award.
Milner Institute to showcase collaboration and innovation at BioTrinity 2026
We’re delighted to announce that the Milner Therapeutics Institute will play an active role at BioTrinity 2026. with both a dedicated showcase session and participation in a key panel discussion focused on collaboration in life sciences.
Cathy Tralau-Stewart discusses strengthening UK therapeutic translation in Drug Discovery World
Professor Cathy Tralau-Stewart, Executive Director of the Milner Therapeutics Institute, has continued her thought leadership work with an article in Drug Discovery World.
Functional Genomics Screening Laboratory wins OBN Award for Most Impactful Industry Collaboration
The Functional Genomics Screening Laboratory, based at the Milner Therapeutics Institute, has won an OBN Award in the category of Most Impactful Industry Collaboration.
Daiichi Sankyo joins Milner Therapeutics Consortium
Daiichi Sankyo has joined the Milner Therapeutics Consortium as our tenth pharma partner.
Milner Institute announces launch of Bio-spark 2025
Early career scientists interested in entrepreneurship can apply for the 2025-26 Bio-spark programme until 13 October.
Milner Therapeutics Institute announced as finalist for 2025 OBN Award
The OBN Awards is a highly regarded awards programme for the Life Sciences industry.
Milner Therapeutics Institute featured in AstraZeneca-University of Cambridge partnership impact report
The Milner Therapeutics Institute is delighted to be featured in a new report celebrating a decade of partnership and impact between AstraZeneca and the University of Cambridge
Milner Institute connects pioneering science with investment at 2025 Pitch Day
The 2025 Pitch Day brought together a vibrant mix of biotech innovators, investors, and translational science leaders.
Milner Therapeutics Symposium showcases innovation in translational science
Hosted at West Road Concert Hall in Cambridge, the Symposium brings together leading minds from academia and industry to showcase cutting-edge research and its translation into novel therapeutics.
Vellos – a company founded by Milner Institute Director Sir Tony Kouzarides – announces partnership with Fifty Years, a renowned pre-seed and seed focused VC firm
Vellos has announced a new partnership with Fifty Years. The partnership will support and inspire the next generation of entrepreneurs across the UK’s deep tech and life sciences sectors.
Milner Institute signs MOU with Yonsei University for joint research in quantum computing
The agreement is expected to serve as a critical foundation for activating international joint research, academic exchange and research collaboration in quantum fields, including quantum computing.
Milner Institute delivers Cambridge-Google AlphaFold Workshop
The workshop brought together leading academic researchers, industry experts and innovators to explore the fundamentals of AlphaFold – an artificial intelligence (AI) program developed by Google DeepMind to predict the 3D structure of proteins.
Milner Institute hosts official opening of new Functional Genomics Screening Laboratory
The new Functional Genomics Screening Laboratory will support world-class research and innovation in the rapidly advancing field of functional genomics, which explores links between genes and disease.
Two Milner Institute bio-incubator companies win cofinitive #21toWatch awards
Two companies based at the Milner Therapeutics Institute bio-incubator have won Cofinitive #21toWatch awards.
Milner Institute partners with Flagship Pioneering and CUHP to accelerate biotech research and innovation
The Milner Therapeutics Institute are delighted to announce a new collaboration with Flagship Pioneering and Cambridge University Health Partners (CUHP), to jointly advance breakthrough scientific research and technologies.
Milner Therapeutics Institute announces 2025 Consortium Call
The 2025 Milner Therapeutics Consortium Call opened on 13 January, with an exciting new focus around pharma-led challenges.
Milner Therapeutics Institute joins Cambridge-ARIA collaboration to create new technologies for transforming brain health
The Milner Therapeutics Institute (MTI) has joined a three-year collaboration with the science funding agency ARIA and multiple Cambridge partners.
Milner Institute celebrates success of 2024 Pitch Day and Therapeutics Symposium
The Milner Therapeutics Institute were delighted to host two sell-out events in Cambridge that brought academics, investors, pharma and biotech companies together.
Milner Therapeutics Institute Director Professor Tony Kouzarides awarded a knighthood in King's Birthday Honours List
Professor Tony Kouzarides, Director of the Milner Therapeutics Institute, has been awarded a knighthood for services to healthcare innovation and delivery.
Milner Therapeutics Institute to house world-class functional genomics laboratory, in new partnership with AstraZeneca and the Medical Research Council
The University of Cambridge announces a new partnership with AstraZeneca and the Medical Research Council (MRC) that will establish a new state-of-the-art functional genomics laboratory at the Milner Therapeutics Institute.
Takeda and Sanofi join Milner Therapeutics Consortium
The Milner Therapeutics Institute are excited to announce that two new pharma partners — Takeda and Sanofi — have joined the Milner Consortium in the past month.
A full house at eighth Milner Therapeutics Symposium
The Milner Therapeutics Institute celebrates the success of its eight annual Symposium, held at West Road Concert Hall on 5th July.